{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:08:03Z","timestamp":1785402483197,"version":"3.56.0"},"reference-count":31,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br. J. Hosp. Med. (Lond)"],"abstract":"<jats:p>Aims\/Background: Statins are first-line therapy for atherosclerotic cardiovascular disease (ASCVD), but their differential effects on glucose metabolism, particularly in the elderly, remain a clinical concern. This study aimed to compare the effects of pitavastatin versus atorvastatin on glucose metabolism in elderly patients with ASCVD. Methods: In this retrospective cohort study conducted at Public Health Clinical Center Affiliated to Shandong University between January 2022 and December 2023, 126 elderly ASCVD patients aged \u226560 years were included and allocated to either the pitavastatin group (4 mg\/day, n = 58) or the atorvastatin group (20 mg\/day, n = 68). Fasting blood samples were collected at baseline and after 12 months of treatment to measure lipid profiles, glucose metabolism parameters, liver function, and renal function. Results: After treatment, the pitavastatin group demonstrated significantly higher levels of high-density lipoprotein cholesterol (HDL-C) (1.41 \u00b1 0.30 mmol\/L vs. 1.26 \u00b1 0.28 mmol\/L, p = 0.005). Regarding glucose metabolism, the pitavastatin group showed lower fasting plasma glucose (5.85 \u00b1 0.70 mmol\/L vs. 6.19 \u00b1 0.85 mmol\/L, p = 0.018) and glycated hemoglobin (6.10 \u00b1 0.42% vs. 6.33 \u00b1 0.51%, p = 0.009). No cases of new-onset diabetes were detected in the pitavastatin group, as compared to the 10.29% rate observed in the atorvastatin group. Multivariate logistic regression analysis confirmed pitavastatin as a protective factor against new-onset diabetes (odds ratio = 0.212, p = 0.018). Conclusion: Compared with atorvastatin, pitavastatin may be associated with better glycemic outcomes and a lower risk of new-onset diabetes in elderly ASCVD patients, supporting its consideration in clinical practice where glycemic control is a concern.<\/jats:p>","DOI":"10.31083\/bjhm56151","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:59:43Z","timestamp":1785398383000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of Pitavastatin Versus Atorvastatin Therapy With Glycaemic Control and New-Onset Diabetes in Older Adults With Atherosclerotic Cardiovascular Disease"],"prefix":"10.31083","volume":"87","author":[{"given":"Hongwen","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, Public Health Clinical Center Affiliated to Shandong University, 250100 Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4810-7638","authenticated-orcid":true,"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Second Ward, Department of Cardiology, The Fifth People\u2019s Hospital of Jinan, 250000 Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Anderson TS, Wilson LM, Sussman JB. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations. JAMA Internal Medicine. 2024; 184: 963\u2013970.","DOI":"10.1001\/jamainternmed.2024.1302"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Mitani H, Suzuki K, Ako J, Iekushi K, Majewska R, Touzeni S, et al. Achievement Rates for Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Atherosclerotic Cardiovascular Disease in a Real-World Setting in Japan. Journal of Atherosclerosis and Thrombosis. 2023; 30: 1622\u20131634.","DOI":"10.5551\/jat.63940"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Lee SJ, Cha JJ, Choi WG, Lee WS, Jeong JO, Choi S, et al. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial. JAMA Cardiology. 2023; 8: 853\u2013858.","DOI":"10.1001\/jamacardio.2023.2222"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Cha JJ, Kim JH, Hong SJ, Lim S, Joo HJ, Park JH, et al. Safety and efficacy of moderate-intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease. Journal of Internal Medicine. 2025; 297: 400\u2013408.","DOI":"10.1111\/joim.20029"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Zhang Z, Zheng H, Zhang L, Su P, Chen X, Xiang A, et al. Atorvastatin enhances LDL receptor-mediated LDL-C uptake and modulates PCSK9 protein expression in pancreatic \u03b2-cells. Islets. 2025; 17: 2479906.","DOI":"10.1080\/19382014.2025.2479906"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lee JE, Yu SH, Kim SR, Ahn KJ, Song KH, Lee IK, et al. Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial. Diabetes & Metabolism Journal. 2024; 48: 730\u2013739.","DOI":"10.4093\/dmj.2023.0077"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Deng B, Li S, You R, Fu Z. Diabetic adverse events associated with three commonly used statins: a disproportionality analysis based on the FDA adverse event reporting system database. Expert Opinion on Drug Safety. 2026; 25: 355\u2013362.","DOI":"10.1080\/14740338.2024.2418325"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Lu MT, Ribaudo H, Foldyna B, Zanni MV, Mayrhofer T, Karady J, et al. Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial. JAMA Cardiology. 2024; 9: 323\u2013334.","DOI":"10.1001\/jamacardio.2023.5661"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Devi G, Singh J, Bal BPS, Chaudhary S. Comparative Effectiveness of Pitavastatin Versus Atorvastatin on Lipid Profile and Blood Sugar in Patients of Diabetic Dyslipidemia: An Open-Label Comparative Study. Cureus. 2025; 17: e90307.","DOI":"10.7759\/cureus.90307"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Garner KK, Colvin C, Cardon B. Pitavastatin Reduces Major Atherosclerotic Cardiovascular Events in Adults with HIV. Journal of the American Board of Family Medicine. 2025; 38: 586\u2013588.","DOI":"10.3122\/jabfm.2025.250014R0"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Fitch KV, Zanni MV, Manne-Goehler J, Diggs MR, Gattu AK, Currier JS, et al. Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention: A Randomized Trial. Annals of Internal Medicine. 2024; 177: 1449\u20131461.","DOI":"10.7326\/ANNALS-24-00944"},{"key":"ref12","unstructured":"Feingold KR. Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease in Patients with Diabetes. In Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, et al. (eds.) Endotext. MDText.com, Inc: South Dartmouth (MA). 2000."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Xia X, Chen S, Tian X, Xu Q, Zhang Y, Zhang X, et al. Association of triglyceride-glucose index and its related parameters with atherosclerotic cardiovascular disease: evidence from a 15-year follow-up of Kailuan cohort. Cardiovascular Diabetology. 2024; 23: 208.","DOI":"10.1186\/s12933-024-02290-3"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Wei Z, Wang F, Zhang L, Dai W. Clinical Efficacy of Ezetimibe Combined with Rosuvastatin in the Treatment of Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Therapy. British Journal of Hospital Medicine. 2024; 85: 1\u201313.","DOI":"10.12968\/hmed.2024.0457"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Li S, Liu HH, Guo YL, Zhu CG, Wu NQ, Xu RX, et al. Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease. Frontiers in Endocrinology. 2022; 13: 860698.","DOI":"10.3389\/fendo.2022.860698"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 139: e1082\u2013e1143.","DOI":"10.1161\/CIR.0000000000000625"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Journal of the American College of Cardiology. 2018; 72: 2231\u20132264.","DOI":"10.1016\/j.jacc.2018.08.1038"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009; 40: 2276\u20132293.","DOI":"10.1161\/STROKEAHA.108.192218"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Sadeq A, Elnour AA, Farah FH, Ramadan A, Baraka MA, Don J, et al. A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin. Current Reviews in Clinical and Experimental Pharmacology. 2023; 18: 120\u2013147.","DOI":"10.2174\/2772432817666220531115314"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Vo NX, Pham HL, Bui TT, Bui TT. Systematic Review on Efficacy, Effectiveness, and Safety of Pitavastatin in Dyslipidemia in Asia. Healthcare. 2024; 13: 59.","DOI":"10.3390\/healthcare13010059"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Arsh H, Ali A, Khenhrani RR, Simran F, Dino U, Tamang S, et al. Efficacy and Safety of Pitavastatin in Patients with Impaired Glucose Tolerance: An Updated Review. Current Problems in Cardiology. 2023; 48: 101981.","DOI":"10.1016\/j.cpcardiol.2023.101981"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Palit SP, Patel R, Parmar N, Rathwa N, Dalvi N, Ramachandran AV, et al. Repurposing Pitavastatin and L-Glutamine: Replenishing \u03b2-Cells in Hyperlipidemic Type 2 Diabetes Mouse Model. Life. 2023; 13: 929.","DOI":"10.3390\/life13040929"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Cederberg H, Stan\u010d\u00e1kov\u00e1 A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015; 58: 1109\u20131117.","DOI":"10.1007\/s00125-015-3528-5"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Seo WW, Seo SI, Kim Y, Yoo JJ, Shin WG, Kim J, et al. Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases. Cardiovascular Diabetology. 2022; 21: 82.","DOI":"10.1186\/s12933-022-01524-6"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Shehab A, Elnour AA, Bhagavathula AS, Kurian JP, Hassan G, AlZaabi S, et al. A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin. Current Diabetes Reviews. 2021; 17: e122820189541.","DOI":"10.2174\/1573399817666201228164243"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Carmena R, Betteridge DJ. Diabetogenic Action of Statins: Mechanisms. Current Atherosclerosis Reports. 2019; 21: 23.","DOI":"10.1007\/s11883-019-0780-z"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Reith C, Preiss D, Blackwell L, Emberson J, Spata E, Davies K, et al. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. The Lancet. Diabetes & Endocrinology. 2024; 12: 306\u2013319.","DOI":"10.1016\/S2213-8587(24)00040-8"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Singh H, Kaur S, Kaushal P, Sharma J, Singla M. Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology. 2024; 17: 1173\u20131181.","DOI":"10.1080\/17512433.2024.2433603"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Moroi M, Nagayama D, Hara F, Saiki A, Shimizu K, Takahashi M, et al. Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. International Journal of Cardiology. 2020; 305: 139\u2013146.","DOI":"10.1016\/j.ijcard.2020.01.006"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Srichatrapimuk S, Wongsa A, Sungkanuparph S, Kiertiburanakul S, Tassaneetrithep B, Phuphuakrat A. Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study. AIDS Research and Therapy. 2023; 20: 13.","DOI":"10.1186\/s12981-023-00506-2"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Erlandson KM, Orkaby AR, Umbleja T, Ribaudo HJ, Brown TT, Zanni MV, et al. Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIV. JACC. Advances. 2025; 4: 102077.","DOI":"10.1016\/j.jacadv.2025.102077"}],"container-title":["British Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/7\/10.31083\/BJHM56151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:00:18Z","timestamp":1785398418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/BJHM\/87\/7\/10.31083\/BJHM56151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S1750-8460(26)03298-0"],"URL":"https:\/\/doi.org\/10.31083\/bjhm56151","relation":{},"ISSN":["1750-8460","1759-7390"],"issn-type":[{"value":"1750-8460","type":"print"},{"value":"1759-7390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"56151"}}